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Abstract
Autosomal dominant lateral temporal epilepsy (ADTLE) is a focal epilepsy syndrome
caused by mutations in the LGI1 gene, which encodes a secreted protein. Most ADLTE-
causing mutations inhibit LGI1 protein secretion, and only a few secretion-positive mis-
sense mutations have been reported. Here we describe the effects of four disease-causing
nonsynonymous LGI1 mutations, T380A, R407C, S473L, and R474Q, on protein secre-
tion and extracellular interactions. Expression of LGI1 mutant proteins in cultured cells
shows that these mutations do not inhibit protein secretion. This finding likely results from
the lack of effects of these mutations on LGI1 protein folding, as suggested by 3D protein
modelling. In addition, immunofluorescence and co-immunoprecipitation experiments
reveal that all four mutations significantly impair interaction of LGI1 with the ADAM22 and
ADAM23 receptors on the cell surface. These results support the existence of a second
mechanism, alternative to inhibition of protein secretion, by which ADLTE-causing LGI1
mutations exert their loss-of-function effect extracellularly, and suggest that interactions of
LGI1 with both ADAM22 and ADAM23 play an important role in the molecular mechanisms
leading to ADLTE.
Author Summary
Temporal lobe epilepsy is the most common form of focal epilepsy. It is frequently associ-
ated with structural brain abnormalities, but genetic forms caused by mutations in major
genes have also been described.Autosomal dominant lateral temporal epilepsy (ADLTE)
is a familial condition characterized by focal seizures with prominent auditory symptoms.
ADLTE-causing mutations are found in the LGI1 gene in about 30% of affected families.
LGI1 encodes a protein, LGI1, that is secreted by neurons. Most LGI1mutations suppress
protein secretion, thereby preventing protein function in the extracellular environment. In
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this paper, we examine the effects of four LGI1mutations and show that they do not
inhibit secretion of the LGI1 protein but impair its interaction with the neuronal receptors
ADAM22 and ADAM23. In agreement with these findings, a three- dimensional model of
the protein predicts that these mutations have no impact on LGI1 structure but instead
may affect amino acids that are critical for interactions with ADAM receptors. Our results
provide novel evidence for an extracellularmechanism through which mutant LGI1 pro-
teins cause ADLTE and strengthen the importance of LGI1-ADAM22/23 protein complex
in the mechanisms underlying ADLTE.
Introduction
Mutations in the leucine-rich, glioma-inactivated 1 (LGI1) gene cause autosomal dominant
lateral temporal epilepsy (ADTLE) [1,2], a genetic epilepsy syndrome characterized by focal
seizures with prominent auditory or aphasic symptoms, normal magnetic resonance imag-
ing, and usually benign evolution [3–5]. ADLTE is inherited in autosomal dominant fashion
with reduced penetrance [6,7], and LGI1mutations are found in about 30% of families with
this syndrome [7]. To date, more than 30 ADLTE-causing mutations have been detected
throughout the protein-coding region of LGI1, resulting in either protein truncation or sin-
gle amino acid substitutions [8,9].
LGI1 is mainly expressed in neurons [1,10,11] and shows no similarity to known ion chan-
nels. The predicted structure of the LGI1 protein comprises a signal peptide, four leucine-rich
repeats (LRRs) [12], and seven repeats named EPTP [13] or EAR [14] likely forming a beta-
propeller structural domain [15]. Both LRR and beta-propeller domains mediate protein-pro-
tein interactions [15,16].
The LGI1 protein is secreted [10,17,18], and most ADLTE-causing LGI1mutations inhibit
protein secretion [10,17,19–21], consistent with a loss-of-function effect of mutations. We
recently reported the first disease-causingLGI1mutation (R407C) with no inhibitory effect on
LGI1 secretion [22].
LGI1 has been implicated in various functions, some of which are mediated by interactions
with two ADAM (A Disintegrin And Metalloprotease domain) receptors. LGI1 has been
shown to bind to the postsynaptic receptor ADAM22 and this ligand-receptor complex partic-
ipates in the control of synaptic strength at excitatory synapses [23]. It also binds to ADAM23
to stimulate neurite outgrowth both in vitro and in vivo [24] and may act as a trans-synaptic
protein connecting the pre-synaptic ADAM23 with the post-synaptic ADAM22 receptors
[25]. Though different in nature, each of these functionsmay potentially be related to epilepsy
if impaired by mutations of LGI1 that prevent or disturb interactions with ADAM22 and
ADAM23 receptors.
Recent work has shown that serum LGI1 autoantibodies from patients with limbic
encephalitis (LE), which is characterized by cognitive dysfunction and seizures [26, 27], pre-
vent interaction of LGI1 with ADAM22 [28]. It has also been shown that some ADLTE-
related mutations allowing secretion of LGI1 impair its binding to ADAM22 but not to
ADAM23 [29]. In this paper we show that secretion-positive LGI1 mutations impair extracel-
lular binding to both ADAM22 and ADAM23 receptors, providing further evidence for the
importance of the LGI1-ADAM22/23 protein complex in the molecularmechanisms under-
lying ADLTE.
LGI1 Mutations Impair Binding to ADAM Receptors
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Results
Selection of study mutations
Previous 3D modelling of the LGI1 protein [30] predicted that some ADLTE-causing, nonsy-
nonymous mutations in the C-terminal EPTP (beta-propeller) domain could allow secretion of
the mutant protein and exert their pathogenic effects extracellularly, suggesting a distinction
between correct protein folding and physiological function. In the present study, we used the
3D model of the LGI1 EPTP domain to envisage the possible effects of four disease-causing
mutations, T380A, R407C, S473L and R474Q, on the structure or function of this protein
region. The genetic features of these mutations are summarized in Table 1. The clinical features
associated with three of them have been described [22,31,32], whereas the phenotype caused by
the T380A mutation will be described elsewhere.
In silico prediction of the effects of study mutations
Fig 1 shows the LGI1 EPTP domain with the T380A, S473L, R474Q, and R407Cmutated resi-
due positions highlighted and additional information on conservation and electrostatics on the
protein surface. All four mutated residues lie on the surface of the beta-propeller domain
within or very close to a ring of conserved residues located on the top surface, which has been
predicted to be crucial for the protein interactions mediated by the EPTP domain [30]. Amino
acid substitutions perturbing the organization of this area may affect LGI1 function by altering
the interaction surface selectively while leaving the protein fold virtually unaffected. This situa-
tion is remarkably different from that predicted for mutations suppressing LGI1 secretion,
which likely alter the folding of either LRR or EPTP domain [see ref. 30], and may provide
valuable clues into LGI1 function arising through protein-protein interactions.
Study mutations do not inhibit LGI1 secretion
The inability of the R407C substitution to suppress LGI1 secretionwas demonstrated previ-
ously [22]. To ascertain the consequences of the LGI1 c.1138A>G (T380A), c.1418C>T
(S473L), and c.1421G>A (R474Q) mutations on secretion of LGI1, we transfected expression
constructs containing the wild type and mutated LGI1 cDNAs into human embryonic kidney
293T (HEK293T) cells and analyzed cell lysates and concentrated conditionedmedia by west-
ern blot using an anti-LGI1 antibody. All three mutant proteins as well as the wild type control
were detected in the conditionedmedia of transfected cells and, though in variable amounts, in
the cell lysates (Fig 2). We consistently observed in three independent experiments a low
Table 1. Genetic features of study mutations.
Mutation Mutated
ADLTE family
Total number
of patients
Occurrence in
healthy controlsa
Occurrence in ESP
5400 databaseb
Conservation of
mutated residue
Polyphen-2
scored
SIFT
scoree
Reference
T380A 1 5 no no highc 0.937 0.13 [42]
S473L 2 14 no no high 1.000 0.09 [27; 28]
R474Q 1 3 no no high 1.000 0.00 [28]
R407C 1 3 no no high 0.998 0.00 [22]
a 50–150 geographically matched healthy controls were screened for each mutation
b the GO Exome Sequencing Project of the National Heart, Lung, and Blood Institute (http://evs.gs.washington.edu/EVS)
c conservation in all vertebrate species
d 0.000–0.850, benign; 0.851–0.950, possibly damaging; 0.951–1.000, probably damaging
e 0.00–0.05, not tolerated; 0.06–0.20, potentially not tolerated; 0.21–1.00, tolerated.
doi:10.1371/journal.pgen.1006376.t001
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amount of LGI1-T380A in the medium (31% of the secreted wild type protein; S1 Fig), suggest-
ing that secretion of this mutant protein was partially hampered (see Discussion). In contrast,
the LGI1 mutant protein carrying the pathogenic I122K substitution [21] was not secreted
from transfected cells (Fig 2), as previously shown for many other ADLTE-causing single
amino acid substitutions in both LRR and EPTP regions [10,17,19–21]. Thus, according to this
secretion assay, the S473L and R474Qmutations do not inhibit secretion of LGI1, as it was the
case for R407C, whereas T380A allows secretion of part of the mutated protein. For this reason
Fig 1. Mapping of the four mutated residues resulting in secreted LGI1 mutant proteins on the human EPTP beta-
propeller model. In A and B the beta-propeller model is represented as a cartoon in front and in lateral view to the top
surface, respectively. Green spheres indicate atoms of mutated residue side chains resulting in secreted LGI1 mutant
proteins. C: conserved surface of the human EPTP beta-propeller calculated with Consurf colouring from unconserved
(cyan) to strictly conserved (magenta). The conservation degree was calculated between human LGI proteins and their
orthologs (Mus musculus, Rattus norvegicus, Bos taurus, Xenopus tropicalis, and Danio rerio). D: electrostatic surface of the
EPTP beta-propeller (negative charge in red and positive charge in blue).
doi:10.1371/journal.pgen.1006376.g001
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all four study mutations are collectively named here sec+mutations, whereas mutations inhib-
iting LGI1 secretion are termed sec- mutations.
LGI1 mutant proteins have no effects on secretion of co-expressed wild
type LGI1
In ADLTE patients carryingLGI1 heterozygous mutations, allelic wild type and mutant pro-
teins are synthesized in the same neuronal cells. To test whethermutant proteins could perturb
secretion of co-expressedwild type LGI1, we co-transfectedHEK293T cells with wild type
LGI1 tagged with green fluorescent protein (GFP) and either LGI1-R407C (sec+) or
LGI1-I122K (sec-) flagged constructs and determined the amounts of secreted LGI1-GFP by
western blot. Fig 3 shows that neither the sec+ nor the sec- mutant proteins altered the amount
of secreted LGI1-GFP. Repeated experiments yielded consistent results, indicating that both
types of mutant proteins do not interfere with the secretion process of wild type LGI1 synthe-
sized in the same cells.
Study mutations affect interactions with ADAM22/23:
Immunofluorescence
To investigate whether the four sec+mutations affected the interaction of LGI1 with
ADAM22/23 receptors, we overexpressed the wild type and mutant LGI1-Flag cDNAs together
with HA-fused ADAM22 or ADAM23 constructs in COS7 cells. Thirty-six hours after co-
transfection, cells were stained with anti-Flag and anti-HA antibodies and double-
Fig 2. Secretion test of wild type and mutated LGI1. Western blot of cell lysates (L) and concentrated
media (M) of HEK293T cells transfected with (left panel) LGI1 wild type or sec+ mutant, c.1138A>G (T380A),
c.1418C>T (S473L), and c.1421G>A (R474Q), expression constructs, or with (right panel) the LGI1 sec-
mutant, c.365T>A (I122K), construct. Bands were revealed with an anti-LGI1 antibody. Ponceau S staining
of the blots are shown below. Vector, empty vector; MW, molecular weight markers.
doi:10.1371/journal.pgen.1006376.g002
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immunofluorescence analysis was carried out using confocal imaging. As exemplified in Fig 4,
the wild type LGI1 protein, when co-expressed with either ADAM22 or ADAM23, mostly co-
localizedwith either receptor on the cell membrane, whereas LGI1 mutant molecules failed to
interact or interacted poorly with ADAM22 and ADAM23 receptors. This was consistently
observed in three different experiments. Overall, the percentage of sec+mutant proteins bound
to either ADAM receptor on the cell membrane (0–33%) was significantly lower than that of
wild-type LGI1 (76–88%; Chi-square test, p< 0.0001) (Table 2).
Secreted LGI1 binds to the extracellular domain of ADAM22
Blood sera from patients with LE containing high titre of LGI1 autoantibodies [26,27] have
been shown to neutralize the LGI1-ADAM22 interaction [28]. To show that co-expressed
LGI1 and ADAM22 interact on the cell surface, we co-transfectedwild type LGI1-Flag and
Fig 3. Secretion of wild type LGI1 co-expressed with LGI1 mutant proteins. Western blot of
concentrated media of HEK293T cells co-transfected with GFP-tagged wild type (wt) LGI1 and one of the
indicated Flag-tagged LGI1 constructs: wt, R407C (sec+), or I122K (sec-). Bands were revealed with an anti-
LGI1 antibody. IgG gel loading control added to cell culture medium prior concentration is shown below.
Vector, empty vector; MW, molecular weight markers.
doi:10.1371/journal.pgen.1006376.g003
LGI1 Mutations Impair Binding to ADAM Receptors
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Fig 4. Interaction between secreted LGI1 and ADAM22 (panel A) or ADAM23 (panel B) on the cell membrane.
COS7 cells were transiently co-transfected with wild type or mutated LGI1-Flag and HA-tagged ADAM22 or ADAM23
expression constructs. Thirty-six hours after transfection, the LGI1 proteins were labelled with anti-Flag antibody (red),
then cells were permeabilized, and ADAM proteins were stained with anti-HA antibody (green). Each panel displays
representative confocal microscopy images, where wild type LGIi1 co-localized with ADAM receptors on the cell surface,
whereas mutant LGI1 proteins failed to interact with ADAM receptors. Scale bars, 10 μm.
doi:10.1371/journal.pgen.1006376.g004
Table 2. Percentage of cells with LGI1 (wild type or mutated) bound to either ADAM22 or ADAM23 receptor on the cell membrane.
LGI1
WT T380A R407C S473L R474
ADAM22 Total cells 115 81 90 97 86
Membrane-bound LGI1 87 (76%) 0 (0%) 32 (36%) 3 (3%) 11 (13%)
ADAM23 Total cells 107 78 72 63 62
Membrane-bound LGI1 94 (88%) 0 (0%) 21 (29%) 10 (16%) 14 (23%)
All frequency differences between wild-type (WT) and mutated LGI1 are statistically significant (Chi-square test, p<0.0001).
doi:10.1371/journal.pgen.1006376.t002
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HA-ADAM22 cDNAs into COS7 cells that were cultured in conditionedmedium containing
serum from an LE patient. We consistently found in three different experiments that increasing
concentrations of LE serum in the conditionedmedia progressively reduced binding of LGI1 to
membrane-boundADAM22 (total cell counts in Table 3). This result demonstrates that
secreted LGI1 binds to the extracellular domain of ADAM22, and that this interaction is dis-
turbed by extracellular LGI1 autoantibodies.
Study mutations affect interactions with ADAM22/23: Co-
immunoprecipitation
To independently assess whether LGI1 mutations affect binding to ADAM22 and ADAM23,
we performed co-immunoprecipitation assays fromHEK293T cells overexpressing HA-tagged
ADAM22 or HA-ADAM23 and LGI1-Flag. As shown in Fig 5A, HA-ADAM22, which is pres-
ent in both immature (110 kDa) and mature (90 kDa) forms as previously observed
(PMID:20156119), efficiently co-precipitated wild type LGI1. Instead, all LGI1 sec+mutations
affected LGI1-ADAM22 interactions: the T380A mutation completely disrupted the interac-
tion, the S473L mutation almost abolished it, whereas R407C and R474Q reduced the affinity
for ADAM22. We also assessed the effect of sec+mutations on LGI1-ADAM23 interaction
using co-immunoprecipitation. As shown in Fig 5B, only wild type LGI1 was clearly immuno-
precipitated by ADAM23, consistent with the results obtained with ADAM22, while pathologi-
cal LGI1 mutations displayed reduced affinity for ADAM23. We obtained consistent results
from two experiments. In both cases expression of HA-ADAM23 was found to be lower than
that of HA-ADAM22, resulting in a lower efficiencyof LGI1 immunoprecipitation.
Discussion
We show in this paper that several ADLTE-causing LGI1mutations affecting amino acids of
the C-terminal EPTP domain allow protein secretion and reduce affinity of secreted LGI1 for
the ADAM22 and ADAM23 neuronal receptors. We also show that secreted LGI1 binds to
ADAM22 on the cell surface, which was assumed but not demonstrated in previous works, and
that secretion of wild type LGI1 is not influenced by LGI1 mutant proteins co-expressed in the
same cells, ruling out any dominant-negative effect of both sec- and sec+mutant proteins on
trafficking and secretion of wild type LGI1.
Inhibition of secretion has long been the sole demonstrated mechanism by which LGI1
mutations cause loss of protein function [8]. Recently we and others reported ADLTE-causa-
tive LGI1mutations that do not inhibit protein secretion [22, 29], indicating that LGI1 muta-
tions can be either secretion-defective (sec-) or secretion-competent (sec+). Both types of
mutations have loss-of-function effects, but sec+mutations appear to exert their effect
Table 3. Proportion of cells with LGI1-ADAM22 complex on the outer membrane surface in the pres-
ence or absence of LE patient serum.
LE serum (%) Total cells Cells with membrane-bound LGI1
0 115 87 (76%)
2.5 273 102 (37%)
5 254 98 (38%)
10 236 47 (20%)
A statistically significant difference (P<0.0001) was observed for all LE serum concentrations versus control
(0% serum)
doi:10.1371/journal.pgen.1006376.t003
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extracellularly by decreasingmolecular affinity for both ADAM22 and ADAM23. Overall, out
of the 22 LGI1missensemutations tested for secretion [10,17,19–22,29,33, and present work],
four (18%) are sec+, all giving rise to an amino acid substitution in the EPTP domain. The
presence of a comparatively large fraction of ADLTE-causing mutations that do not affect
LGI1 secretion suggests that they allow the protein fold to be maintained while disrupting
LGI1 interactions with other proteins. The surface residues replaced by sec+mutations might
either be directly responsible for the LGI1-ADAM22/23 interactions, or perturb, when
mutated, the capability of nearby residues to interact with critical amino acids on the surface of
ADAM22 and ADAM23. Particularly, any mutation disturbing the conserved residues forming
a ring on the EPTP top surface (see Fig 1) might weaken the interaction or even abolish it
entirely.
In a recent work, Yakoi et al. [29] showed that the sec+mutation S473L decreased binding
of LGI1 to ADAM22, but interaction with ADAM23 remained unchanged. They concluded
that the pathogenic mechanisms underlying ADLTE in the case of sec+mutations might result
mostly, if not completely, from a dysfunction of the LGI1-ADAM22 complex. In contrast, we
found that sec+mutant proteins exhibit reduced binding affinity to both ADAM22 and
ADAM23. This discrepancymay be explained by the different assays employed. Compared
with the tandem-affinity purification of LGI1 from brain tissue of transgenic mice expressing
mutant proteins used by Yakoi and co-workers, our optimized cell-based assays (36 h incuba-
tion after co-transfection; seeMethods) may be more sensitive in detecting the decreased bind-
ing ability of sec+mutations. Thus, our results suggest that both ADAM receptors likely play a
role in the pathogenesis of ADLTE through their interactions with LGI1.
Genetic disorders that are caused by defects in a ligand for a particular receptor are fre-
quently mirrored by disorders in which that receptor is deficient. However, a causative role for
ADAM22 and ADAM23 in ADLTE has been questioned in genetic studies of families without
LGI1mutations: direct sequencing of ADAM22 exons revealed no disease-causingmutations
Fig 5. LGI1 mutations impair interaction with ADAM22 and ADAM23. HEK293T cells were transiently
co-transfected with (A) HA-ADAM22 or (B) HA-ADAM23 and LGI1 wild-type or mutants. Inputs (6.5% of total
proteins) and HA-immunoprecipitations were separated in SDS-PAGE, transferred and immunoblotted using
the indicated antibody. Co-immunoprecipitations showed that wild type LGI1 interacts with HA-ADAM22 (A)
and HA-ADAM23 (B), while the interaction is abolished in the presence of T380A mutant. LGI1 mutants
R407C, S473L and R474Q displayed a reduced interaction compared to the wild-type. Each of these
experiments was performed twice with similar results. In the experiment shown in panel B, HA-ADAM23
failed to transfect HEK293T cells together with LGI1-S473L.
doi:10.1371/journal.pgen.1006376.g005
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[34,35], and linkage analysis with microsatellite markers within or near the ADAM23 gene
failed to reveal any significant linkage peak [36]. The absence of causative mutations in
ADAM22 and ADAM23, however, is not in contrast with their involvement in the molecular
pathway underlying ADLTE, and this apparent contradiction can be explained in different
ways. It is possible that mutations in these genes have not been detected in the limited set of
ADLTE families tested because they occur at low frequency, a hypothesis supported by recent
studies suggesting a relatively high genetic heterogeneity in ADLTE families free of LGI1muta-
tions [7]. Alternatively, LGI1-associated ADLTE may reflect a partial loss of function of the
LGI1 ligand at both receptor proteins ADAM22 and ADAM23, whereas heterozygous muta-
tions in only one of these receptors may not be sufficient to cause the syndrome. The recent
identification of ADAM22 compound heterozygous mutations in a patient with severe enceph-
alopathy and epilepsy, who inherited the mutations by healthy parents, supports the hypothesis
that ADAM22may primarily be a recessive disease gene [37]. Also, protein models suggesting
that LGI1 is able to interact with ADAM22 and ADAM23 simultaneously [25,30] provide sup-
port to this interpretation, which might also apply to other as yet unknown proteins interacting
with LGI1. Further support to the importance in epileptic disorders of the ligand-receptor
interaction between LGI1 and ADAM22/23 comes from a recent study showing that these
interactions are specifically impaired by LGI1 autoantibodies from the sera of patients with
limbic encephalitis, which is characterized by amnesia and seizures [28]. Reduced binding of
LGI1 to ADAM22/23 may therefore be a pathogenic mechanism for both genetically inherited
and acquired epilepsy disorders.
Recent work has shown that haploinsufficiency caused by sec- mutations does not result
from lack of protein secretion but from intracellular degradation of misfoldedmutant proteins
by the endoplasmic reticulum protein quality-control mechanisms [29]. This is in agreement
with the predictions of our 3D model for sec- mutations, which likely destabilize protein fold-
ing [30], and also provides a possible explanation for the low amount of secreted LGI1-T380A
we observed.This mutant protein was found virtually absent in the cell culture medium in a
previous work [29], in which the T380A substitution was therefore regarded as a sec- mutation.
Instead, we found a low but consistently detectable amount of LGI1-T380A in the cell medium
(S1 Fig). Although we regarded it as a sec+mutation for simplicity, the T380A substitution is
not readily classifiable because only a relatively low proportion of the mutant protein appears
to be secreted, whereas the rest of the mutant moleculesmight be degraded in the endoplasmic
reticulum, possibly due to a mild alteration of the EPTP domain folding resulting from this
mutation. In any case, the secreted LGI1-T380A protein failed to bind to both ADAM recep-
tors under our experimental conditions, suggesting a loss-of-function effect of this genetic
defect. Despite its possible mixed effects on protein stability and secretion, this mutation leads
to the same clinical phenotype caused by LGI1 sec+ as well as sec- mutations.
The discovery of sec+mutations provides new opportunities for investigating LGI1 func-
tions and understanding their relevance to ADLTE. For example, the study of sec+mutant pro-
teins in in vitro cell systems may help clarify whether some functions attributed to LGI1, such
as control of dendrite growth and cell adhesion, are related to ADLTE; also, animal models
incorporating these types of mutations may provide new insights into the role of LGI1 in pro-
cesses such a synaptic maturation and transmission. These studies will improve our compre-
hension of the pathogenic mechanisms of ADLTE as a paradigm of non-ion channel idiopathic
epilepsy. Moreover, new therapeutic strategies that make use of chemical correctors to restore
protein folding might be effectivewith LGI1 sec- mutations [29] but not with sec+mutations,
which have little or no effect on protein folding. Therefore, a correct classification of LGI1
mutations based on their effects of protein folding and secretionmight have in the future
important therapeutic implications.
LGI1 Mutations Impair Binding to ADAM Receptors
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Materials and Methods
In silico analysis
Both the LGI1 beta-propeller structuremodel as recently published [30] and the crystal struc-
ture of ADAM22, PDB identifier 3G5C [38], were visualized using PyMOL (DeLano Scientific,
URL: http://pymol.sourceforge.net/). The degree of conservation on the protein surface was
mapped with ConSurf [39], using all known LGI1 through LGI4 homologs and the ADAM22
orthologs from OMAbrowser [40] respectively. The electrostatic surface was calculated with
BLUUES [41] and mapped on the protein structures. The pathogenicity of four LGI1 muta-
tions has been predicted also using the two widely used computational methods, SIFT (http://
sift.bii.a-star.edu.sg/) and Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/). The SIFT score
indicates the degree of conservation derived from a sequence alignment of closely related pro-
teins. Polyphen-2 is based on both sequence and structural information. It uses the PSIC (Posi-
tion-Specific Independent Count) software to calculate a profile matrix for each position in the
sequence alignment. The difference between profile scores of allelic variants indicates the prob-
ability of the substitution to be observed in the protein family at that position.
Antibodies
Rabbit anti-LGI1 antibodies were from Abcam (Cambridge, UK; catalog No. ab30868); mouse
anti-HA.11, clone No. 16B12, from Covance (Princeton, NJ, USA); rabbit anti-Flag from
Sigma Aldrich (St. Louis, MO, USA; catalog No. F7425). Secondary antibodies Alexa-Fluor
488-conjugated goat anti-mouse IgG were from Life Technology (Grand Island, NY, USA; cat-
alog No. A11001); and Cy3-conjugated goat anti-rabbit IgG from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA; catalog No. 111-165-003). Horseradish peroxidase-conju-
gated mouse-specific IgG, catalog No. P0260, and horseradish peroxidase-conjugated rabbit-
specific IgG, catalog No. P0448, were from DakoCytomation (Denmark A/S).
LGI1 secretion assay
Cell-basedLGI1 secretion assay was performed as described in detail previously [18]. Briefly,
expression constructs containing the LGI1 wild type or mutant cDNAs were transfected into
HEK293T cells using Lipofectamine 2000 (Life Technology), following the manufacturer
instructions. Twenty-four hours after transfection, cells were washed twice and then re-fed
with serum-freemediumOpti-MEM (Life Technology). After 16–20 hours, the mediumwas
collected and centrifuged to pellet cell debris, and the supernatant was concentrated about 20x
using Centricon YM30 concentrators (Merk-Millipore, Billerica,MA, USA). Cells were lysed
in Triton lysis buffer (25 mM Tris pH 7.4, 150 mMNaCl, 1% (vol/vol) Triton, 10% (vol/vol)
Glycerol, 1mM EDTA) supplemented with proteases and phosphatase inhibitors.
Cell proteins (14 μg/lane) and concentrated media were separated on 12% NuPAGE (Life
Technology) and then electroblotted onto nitrocellulosemembrane. The integrity of theWest-
ern blot was analysed by Red Ponceau staining. Destainedmembranes were blocked with 10%
(w/v) skimmedmilk in tris-buffered saline (TBS) for 1 hr and then incubated with primary
antibody in TBS containing 2% (vol/vol) skimmedmilk for 2 hrs at room temperature. Proteins
immunostainedwith anti-LGI1 antibody were detectedwith a horseradish peroxidase-labelled
secondary antibody and enhanced chemiluminescence reagent and visualized by
autoradiography.
To examine the effect of LGI1 mutant proteins on secretion of wild type LGI1, HEK293T
cells were co-transfectedwith wild type LGI1-GFP and a Flag-containing LGI1 mutant, either
c.1219C>T (R407C) or c.365C>A (I122K), constructs (1.5 ug each). Following cell incubation,
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serum-free conditionedmediumwas concentrated and analyzed by western blot as described
above. As gel loading control, a fixed quantity of IgG (14 ng) was added to 6 ml cell medium
before concentration (60x) so as to load approximately 2 ng of IgG in each gel lane. The IgG
were detectedwith a horseradish peroxidase-labelled secondary antibody. This experiment was
repeated three times to confirm reliability of results.
COS7 cell co-transfection and immunofluorescence
COS7 cells were seeded on sterile glass coverslips and co-transfectedwith wild-type or mutant
LGI1-Flag and HA-tagged ADAM22 or ADAM23 cDNAs (3 ug of total DNA). Thirty-six
hours after transfection, cells were fixed with 4% paraformaldehyde (PFA) at room tempera-
ture for 10 min and blocked with PBS containing 2 mg/ml bovine serum albumin (BSA)
(Sigma-Aldrich) for 40 min. Fixed cells were stained with rabbit anti-Flag antibody (1:300), fol-
lowed by Cy3-conjugated anti-rabbit secondary antibody (1.300). Then, the cells were permea-
bilized with 0.1% Triton X-100 for 10 min, blocked with PBS containing 2mg/ml BSA and
stained with anti-HA monoclonal antibody (1:500), followed by Alexa-Fluor 488-conjugated
anti-mouse secondary antibody (1:500). All the antibodies were diluted in 1% BSA/PBS; this
was followed by washes with PBS. Finally, they were fixed with mounting medium containing
DAPI (Vectashield; Vector Laboratories). Two coverslips were made for every transfection
experiment, and twenty random fields were taken (magnification 400X). For every field the
number of co-immunostained cells (LGI1 and ADAM 22 or ADAM 23) was counted and the
percentage of cells with both signals on the cell surface was estimated. In total, three indepen-
dent experiments were performed. For cell counting, slides were analysed using a Leica-DM
5000B Epifluorescencemicroscope. Confocal images were acquired with a Radiance 2000 con-
focal microscope (BioRad).
The GraphPad software program (http://www.graphpad.com/quickcalcs/) was used to cal-
culate Chi-square and the two-tailed P-value to compare the frequency of membrane-bound
LGI1 proteins between cells carrying the wild type LGI1 protein and cells expressing LGI1
mutated proteins.
Blood serum from a patient with LGI1-positive autoimmune LE was used to investigate
weather interaction of LGI1 with ADAM22 occurred on the outer surface of the cell mem-
brane. COS7 cells were seeded on sterile glass coverslips and co-transfectedwith wild type
LGI1-Flag and HA-tagged ADAM22 cDNAs as described above. Twenty hours after transfec-
tion the mediumwas replaced with serum-freemedium additioned with 2,5%, 5% and 10% LE
patient serum.After twenty-eight hours cells were processed and immunofluorescence analysis
was performed as described above. Statistical analysis was performed as described above.
Co-immunoprecipitation
LGI1-Flag wild-type or clinical mutants were co-transfectedwith HA-ADAM22 or HA-A-
DAM23 into HEK293T cells seeded on a six wells plate. Thirty-six hours after transfection,
cells were lysed in 200 μl of lysis buffer (50 mMTris-HCl, pH 7.5, 1 mM EDTA, 1 mM sodium
orthovanadate, 10 mM sodium β-glycerophosphate, 5 mM sodium pyrophosphate, 0.27 M
sucrose and 1% (w/v) Tween 20 in the presence of lx protease inhibitor cocktail (Sigma
Aldrich) and incubated on ice for 20 minutes. Lysates were subsequently clarified by centrifu-
gation at 14000 g for 20 minutes and 0.5 mg of total proteins in 500 μl of volume were incu-
bated with 0.5 μg of mouse monoclonal anti-HA antibody (Roche). After 2 hours of incubation
at 4°C with gentle rocking, 20 μl of Protein G sepharose (GE Healthcare Life Sciences) were
supplemented and incubated 1 hour at 4°C. After 5 washes in washing buffer (50 mM Tris/
HCl, pH 7.5, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium β-glycerophosphate,
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5 mM sodium pyrophosphate, 0.27 M sucrose, 1% (v/v) tween 20 and 250 mMNaCl), proteins
were eluted in 2x sample buffer (Invitrogen), separated in NuPAGE 4–12% (Life Technology)
and electro-blotted on polyvinylidene fluoridemembrane (PVDF) (Merk-Millipore). PVDF
membranes were saturated with 10% skimmedmilk in TBS supplemented with 0.05% tween
20 and proteins detected using mouse primary anti-HA (1:1000) and rabbit anti-LGI1 (1:1000)
antibodies and secondary antibodies conjugated with horseradish peroxidasemouse- specific
IgG and rabbit-specific IgG (both diluted 1:2000).
Supporting Information
S1 Fig. Quantification of secretion levels of three LGI1 mutant proteins. Protein amounts
detected in cell media by western blot in three independent experiments are expressed in per-
centage as compared to wild type LGI1.
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